Blogs

Digital Health revolution is around the corner and it won’t be long when this technology will start affecting our daily life and the way we consume healthcare products and services. The divide however is still a long one and from a consumer standpoint, there is a lack of understanding of what really entails digital health. This is an information gap which will definitely need to be addressed as more tangible products and solutions are available

There are four areas of innovation that are noticeable both in isolation and how they feed into each other for a transformation in cancer care “Big data” and Bioinformatics – rapidly developing data management systems and analytics e.g. NGS that will enable us to collect, analyze and learn from vast amounts of real-world data – not just the 3% of patients that participate in clinical trials. Outcome –there will be an increasing slicing and dicing(cancer panomics) of

For more than half a century, patients with Non-Valvular Atrial Fibrillation (NVAF) have been using vitamin K antagonist (Warfarin) to prevent stroke and thromboembolism. Warfarin has proved to be effective, however, it comes with its own baggage of side effects. The use of warfarin is limited due to risk of bleeding, regular INR monitoring and possible food-drug interactions; resulting in poor patient compliance. In recent years, a number of New Oral Anticoagulants (or Non-Vitamin K

Mylan’s Phase 3 clinical read out was the biosimilar show stopper at ASCO 2016. The biosimilar awareness amongst the attendees was reflected by the full house attendance of biosimilar sessions and presentations throughout the conference. The clinical data from the Phase 3 HERiTAge study, comparing Mylan’s MYL-1401O, potential trastuzumab biosimilar and Roche’s Herceptin®, demonstrated clinical equivalence. The oral presentation made by Dr. Hope Rugo triggered discussion on its inclusion in the clinical practice and need

The year 2015 marked the approval of the first biosimilar via the BPCIA pathway in USA. The murmurs of biosimilars could be heard in the corridors of ASCO-2015. A total of 3 clinical read-outs and industry sponsored activities marked the largest oncology congregation of 2015. Russia-based biosimilar developer, Biocad presented Phase 3 clinical data of its potential bevacizumab biosimilar. The candidate drug, BCD-021, demonstrated equivalence to Avastin® (marketed by Roche) in a comprehensive comparability exercise

Biopesticides are used for high-quality crop yield for the increasing population and growing organic food demand. Many multinational players have entered into the research and development of biopesticides for diversified crop types. It presents a business opportunity in coming years.